




Effect of Dexmedetomidine on Biochemical Recurrence in
Patients after Robot-Assisted Laparoscopic Radical
Prostatectomy: A Retrospective Study
Young Chul Yoo 1,† , Won Sik Jang 2,† , Ki Jun Kim 1, Jung Hwa Hong 3 , Sunmo Yang 1 and Na Young Kim 1,*


Citation: Yoo, Y.C.; Jang, W.S.; Kim,
K.J.; Hong, J.H.; Yang, S.; Kim, N.Y.
Effect of Dexmedetomidine on
Biochemical Recurrence in Patients
after Robot-Assisted Laparoscopic
Radical Prostatectomy: A
Retrospective Study. J. Pers. Med.
2021, 11, 912. https://doi.org/
10.3390/jpm11090912
Academic Editor: Ramesh Narayanan
Received: 8 July 2021
Accepted: 12 September 2021
Published: 13 September 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University
College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea; seaoyster@yuhs.ac (Y.C.Y.);
kkj6063@yuhs.ac (K.J.K.); sunmong@yuhs.ac (S.Y.)
2 Department of Urology and Urological Science Institute, Yonsei University College of Medicine,
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea; sindakjang@yuhs.ac
3 Department of Policy Research Affairs, National Health Insurance Service Ilsan Hospital, 100 Ilsan-ro,
Ilsandong-gu, Goyang-si 10444, Gyeonggi-do, Korea; jh_hong@nhimc.or.kr
* Correspondence: knnyyy@yuhs.ac; Tel.: +82-2-2228-4435
† These authors contributed equally to this work.
Abstract: The usage of dexmedetomidine during cancer surgery in current clinical practice is debat-
able, largely owing to the differing reports of its efficacy based on cancer type. This study aimed
to investigate the effects of dexmedetomidine on biochemical recurrence (BCR) and radiographic
progression in patients with prostate cancer, who have undergone robot-assisted laparoscopic radical
prostatectomy (RALP). Using follow-up data from two prospective randomized controlled studies,
BCR and radiographic progression were compared between individuals who received dexmedeto-
midine (n = 58) and those who received saline (n = 56). Patients with complete follow-up records
between July 2013 and June 2019 were enrolled in this study. There were no significant between-
group differences in the number of patients who developed BCR and those who showed positive
radiographic progression. Based on the Cox regression analysis, age (p = 0.015), Gleason score
≥ 8 (p < 0.001), and pathological tumor stage 3a and 3b (both p < 0.001) were shown to be signif-
icant predictors of post-RALP BCR. However, there was no impact on the dexmedetomidine or
control groups. Low-dose administration of dexmedetomidine at a rate of 0.3–0.4 µg/kg/h did not
significantly affect BCR incidence following RALP. In addition, no beneficial effect was noted on
radiographic progression.
Keywords: biochemical recurrence; dexmedetomidine; prostate cancer; radiographic progression
1. Introduction
Several reports have highlighted the importance of understanding and defining vari-
ous factors during the perioperative period that may affect the postoperative long-term
outcomes of patients with cancer [1,2]. Although the perioperative period is relatively short,
it involves numerous risk factors and presents unexploited opportunities for improving the
overall patient survival [1]. The anesthetic and analgesic approaches are prominent aspects
of surgery that may be manipulated to improve various endocrinological, immunological,
and cancer-related outcomes [2–4].
Recently, clinical studies on the effect of dexmedetomidine, an alpha-2 adrenoreceptor
agonist commonly used in the perioperative period, have been performed for several
types of cancer. The effects elicited by dexmedetomidine, particularly the sympatholytic
effects, are suggestive of its benefits in the perioperative care of patients with cancer [5,6].
Further, a recent in vivo study has shown that dexmedetomidine inhibits esophageal cancer
progression via miR-143-3P/epidermal growth factor receptor pathway substrate 8 [7].
However, results of in vitro and in vivo studies of dexmedetomidine revealed that tumor
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cell proliferation and metastasis are promoted, and overall survival is reduced [8–18]. In
contrast, Owuso et al. reported that dexmedetomidine did not affect the survival of patients
who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
for peritoneal carcinomatosis [19]. Hence, with variable results reported for different types
of cancers, the use of dexmedetomidine during cancer surgery is currently debatable; this
may be attributed to a lack of robust prospective data.
We previously conducted two prospective, double-blinded, randomized controlled
trials to evaluate the effect of dexmedetomidine on intraocular pressure (IOP) and heart-
rate corrected QT (QTc) intervals during robot-assisted laparoscopic radical prostatectomy
(RALP) [20,21]. The patients included in the aforementioned studies had undergone RALP
4–6 years ago, which allowed us to assess their cancer status and long-term outcome.
However, to the best of our knowledge, no study has investigated the effects of dexmedeto-
midine on prostate cancer recurrence after RALP. Therefore, this study aimed to investigate
the effects of dexmedetomidine on biochemical recurrence (BCR), which reflects the long-
term oncologic outcomes of prostate cancer in the patients who underwent RALP. Further,
radiographic progression was also evaluated.
2. Materials and Methods
2.1. Study Design and Participants
The protocols of the double-blinded, randomized controlled IOP and QTc trials,
which evaluated the effect of dexmedetomidine on IOP and QTc intervals in patients
who had undergone RALP, have been described previously [20,21]. Sixty-seven patients
were enrolled between July and December 2013 for the IOP trial, and 47 patients were
enrolled between August 2015 and January 2016 for the QTc trial. We obtained additional
ethics approvals from the Institutional Review Board (IRB) and Hospital Research Ethics
Committee (Yonsei University Health System, Seoul, Korea; IRB protocol No. 4-2019-0424)
for this follow-up study. This study was performed in accordance with relevant guidelines
and regulations. The requirement for informed consent from the patients was waived. In
this study, patients with complete follow-up records between July 2013 and June 2019 were
enrolled. Patients who have been treated for other cancers or have incomplete follow-up
data were excluded. For the current study, BCR, radiographic progression status, initial
prostate-specific antigen (PSA) levels, Gleason score, tumor volume, surgical margin status,
pathological tumor stage, and lymph node metastasis were included as variables in this
study. Gleason score was assigned based on the 2005 International Society of Urological
Pathology Modified Gleason System [22]. Pathological tumor stage and lymph node
metastasis (TNM) was determined according to the 7th edition American Joint Committee
on Cancer TNM staging system [23].
2.2. Anesthesia Protocol
Depending on the group, dexmedetomidine (n = 58) (100 mg/mL in a 2-mL vial; Hos-
pira Worldwide, Seoul, Korea) or saline (n = 56) was administered at a rate of 0.3–0.4 µg/kg/h
from the initiation of anesthesia until the end of pneumoperitoneum maintenance. All
patients underwent conventional inhalation anesthesia and were treated using the same
modality. Anesthesia induction was performed using propofol (1.5–2 mg/kg) and rocuro-
nium (0.6–1.2 mg/kg) and was maintained with sevoflurane (0.6–2.3 age-adjusted min-
imal alveolar concentration) and remifentanil (0.02–0.1 µg/kg/min). After induction,
pneumoperitoneum was maintained at 15 mm Hg carbon dioxide in the steep (29◦)
Trendelenburg position.
2.3. Follow-up
For follow-up, the patients returned to the clinic at 3-month intervals for the first
2 years, and then at 6-month intervals for the next 3 years. Thereafter, annual follow-ups for
PSA monitoring were recommended. BCR was defined as any two consecutive increases of
≥0.2 ng/mL in serum PSA levels following RALP [24]. If a patient showed symptomatic
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progression or an increase in PSA levels, follow-up imaging studies, including whole-body
bone scan and abdominal-pelvic computed tomography or magnetic resonance imaging,
were performed. Radiographic progression-free survival was defined as the duration from
RALP to either disease progression based on the imaging studies, or to death as a result of
any cause.
2.4. Statistical Analysis
Continuous and categorical variables were presented as mean (±standard deviation)
and n (%), respectively. Between-group comparisons were performed using an independent
two-sample t-test and a chi-square test, respectively. The log-rank test and Kaplan-Meier
curve analysis were used for between-group comparisons of post-RALP BCR and ra-
diographic progression-free survival for up to 60 months. Additionally, univariate and
multivariate Cox regression analyses were performed to determine the factors that affected
post-RALP BCR and radiographic progression. All statistical analyses were performed
using Statistical Analysis Software version 9.4.
3. Results
Of the original 114 eligible patients, 67 and 47 patients were included in the IOP and
QTc trials, respectively, with none of the patients being excluded due to loss to follow-up.
Finally, 56 and 58 patients were allocated to the control and dexmedetomidine groups,
respectively (Figure 1).




Figure 1. Consort flow diagram. IOP = intraocular pressure; QTc = heart-rate corrected QT interval. 
There were no significant between-group differences in the demographics and oper-
ative variables, except for the administered remifentanil dose (Table 1); the intraoperative 
administered dose of remifentanil was significantly lower in the dexmedetomidine group 
than in the control group (492 ± 169 vs. 731 ± 269 μg; p < 0.001). 
Table 1. Demographics and operative variables. 
Variable Control (n = 56) Dexmedetomidine (n = 58) p Value 
Age (years) 64 ± 9 63 ± 8 0.686 
Body mass index (kg/m2) 24.6 ± 2.1 23.9 ± 2.8 0.131 
ASA physical status   0.412 
I 19 (44%) 24 (56%)  
II 37 (52%) 34 (48%)  
Co-morbidities   0.500 
Hypertension 24 (43%) 27 (47%)  
Diabetic mellitus 7 (13%) 5 (9%)  
Pneumoperitoneum duration (min) 117 ± 33 109 ± 34 0.202 
Surgery duration (min) 150 ± 31 143 ± 34 0.246 
Anesthesia duration (min) 206 ± 33 194 ± 34 0.075 
Administered dose of remifentanil (μg) 731 ± 269 492 ± 169 <0.001 * 
Figure 1. Consort flow diagram. I i c lar pre sure; QTc = heart-rate corrected QT interval.
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There were no significant between-group differences in the demographics and opera-
tive variables, except for the administered remifentanil dose (Table 1); the intraoperative
administered dose of remifentanil was significantly lower in the dexmedetomidine group
than in the control group (492 ± 169 vs. 731 ± 269 µg; p < 0.001).
Table 1. Demographics and operative variables.
Variable Control (n = 56) Dexmedetomidine (n = 58) p Value
Age (years) 64 ± 9 63 ± 8 0.686
Body mass index (kg/m2) 24.6 ± 2.1 23.9 ± 2.8 0.131
ASA physical status 0.412
I 19 (44%) 24 (56%)
II 37 (52%) 34 (48%)
Co-morbidities 0.500
Hypertension 24 (43%) 27 (47%)
Diabetic mellitus 7 (13%) 5 (9%)
Pneumoperitoneum duration (min) 117 ± 33 109 ± 34 0.202
Surgery duration (min) 150 ± 31 143 ± 34 0.246
Anesthesia duration (min) 206 ± 33 194 ± 34 0.075
Administered dose of remifentanil (µg) 731 ± 269 492 ± 169 <0.001 *
Administered dose of ephedrine (mg) 4 ± 7 5 ± 7 0.371
Intraoperative fluid input and output (mL)
Crystalloid 1346 ± 345 1294 ± 597 0.566
Colloid 486 ± 184 522 ± 178 0.293
Blood loss 337 ± 179 271 ± 198 0.066
Urine output 352 ± 196 359 ± 224 0.867
Values are presented as mean ± standard deviation or number of patients (%). * p <0.05. ASA, American Society of Anesthesiologists.
Table 2 demonstrates the postoperative outcomes and pathologic variables. There were
no significant between-group differences in the number of patients who developed BCR
and those who demonstrated positive radiographic progression. Other variables, including
initial PSA levels, Gleason score, tumor volume, surgical margin status, pathological tumor
stage, and lymph node metastasis did not show differences between the two groups.
Table 2. Postoperative outcomes and pathological variables.
Variable Control (n = 56) Dexmedetomidine (n = 58) p Value
Biochemical recurrence 21 (38%) 23 (40%) 0.813
Positive radiographic progression 7 (13%) 5 (9%) 0.500
Postoperative hospital stays (days) 4 ± 2 4 ± 2 0.553
Initial PSA level (ng/mL) 13.5 ± 15.2 17.7 ± 21.0 0.218
Gleason score 0.038
6 28 (50%) 16 (28%)
7 17 (30%) 29 (50%)
≥8 11 (20%) 13 (22%)
Tumor volume (cc) 0.976
<1 24 (43%) 24 (41%)
≥1 and <5 23 (41%) 25 (43%)
≥5 9 (16%) 9 (16%)
Surgical margin status 0.394
Negative 39 (70%) 36 (62%)
Positive 17 (30%) 22 (38%)
Pathological tumor stage 0.967
2 37 (66%) 37 (64%)
3a 11 (20%) 12 (21%)
3b 8 (14%) 9 (16%)
Lymph node metastasis >0.999
Negative 54 (96%) 56 (97%)
Positive 2 (4%) 2 (3%)
Values are presented as mean ± standard deviation or number of patients (%). PSA, prostate specific antigen.
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The mean follow-up duration of BCR was 42 [(Interquartile range) IQR, 13–56)]
months in the control group and 36 [IQR, 13–56] months in the dexmedetomidine group.
In the radiographic progression, median follow-up duration in the control group was 52
[IQR, 35–65] and that in the dexmedetomidine group was 49 [IQR, 38–66] months. The
BCR and radiographic progression-free survival for up to 60 months after RALP between
the dexmedetomidine and control groups are demonstrated in Figure 2; no significant
differences were observed between the two groups.




Figure 2. Biochemical recurrence-free survival (A) and radiographic progression-free survival (B) between the control and 
dexmedetomidine groups until the 60-month follow-up after robot-assisted laparoscopic radical prostatectomy. 
Other variables, including initial PSA levels, Gleason score, tumor volume, surgical 
margin status, pathological tumor stage, and lymph node metastasis did not show differ-
ences between the two groups. 
The Cox regression analysis showed that age (Hazards ratio [HR] = 1.05, 95% confi-
dence interval [CI]: 1.01–1.09; p = 0.015), Gleason score ≥ 8 (HR = 11.07, 95% CI: 3.81–32.19; 
p < 0.001), and pathological tumor stage 3a and 3b (HR = 4.92, 95% CI: 2.04–11.88, and HR 
= 8.86, 95% CI: 2.56–30.72, respectively; both p < 0.001) were significant predictors of post-
RALP BCR; however, there was no effect on either the dexmedetomidine or control group 
(Table 3). 
Table 3. Univariate and multivariate analyses of risk factors for biochemical recurrence after RALP (n = 114). 
Variable 
Univariate Multivariate 
HR (95% CI) p Value HR (95% CI) p Value 
Group     
Control 1  1  
Dexmedetomidine 1.09 (0.60–1.96) 0.786 0.80 (0.43–1.47) 0.468 
Age (years) 1.04 (1.00–1.08)  0.038* 1.05 (1.01–1.09) 0.015 * 
Body mass index, kg/m2 1.09 (0.95–1.24) 0.227   
ASA physical status     
I 1    
II 1.82 (0.94–3.53) 0.078   
Co-morbidities     
Hypertension 1.32 (0.73–2.39) 0.353   
Diabetic mellitus 1.60 (0.67–3.78) 0.288   
Pneumoperitoneum duration (min) 0.99 (0.98–1.00) 0.099   
Surgery duration (min) 0.99 (0.98–1.00) 0.142   
Anesthesia duration (min) 0.99 (0.99–1.00) 0.259   
Administered dose of remifentanil (μg) 0.98 (0.96–1.01) 0.200   
Administered dose of ephedrine (mg) 1.03 (0.98–1.07) 0.162   
Intraoperative fluid input and output (mL)     
Crystalloid 1.00 (0.99–1.00) 0.444   
Colloid 1.00 (0.99–1.00) 0.816   
Figure 2. Biochemical recurrence-free survival (A) and radiographic progression-free survival (B) between the control and
dex edeto idine groups until the 60- onth follo -up after robot-assisted laparoscopic radical prostatectomy.
Other variables, including initial PSA levels, Gleason score, tumor volume, surgi-
cal margin status, pathological tumor stage, and lymph node metastasis did not show
differences between the two groups.
The Cox regression analysis showed that age (Hazards ratio [HR] = 1.05, 95% confi-
dence interval [CI]: 1.01–1.09; p = 0.015), Gleason score ≥ 8 (HR = 11.07, 95% CI: 3.81–32.19;
p < 0.001), and pathological tumor stage 3a and 3b (HR = 4.92, 95% CI: 2.04–11.88, and
HR = 8.86, 95% CI: 2.56–30.72, respectively; both p < 0.001) were significant predictors of
post-RALP BCR; however, there was no effect on either the dexmedetomidine or control
group (Table 3).
Table 3. Univariate and multivariate analyses of risk factors for biochemical recurrence after RALP (n = 114).
Variable
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
Group
Control 1 1
Dexmedetomidine 1.09 (0.60–1.96) 0.786 0.80 (0.43–1.47) 0.468
Age (years) 1. 4 (1.00–1.08) 0.038 * 1. 5 (1.01–1.09) 0.015 *
Body mass index, kg/m2 1.09 (0.95–1.24) 0.227
ASA physical status
I 1
II 1.82 (0.94–3.53) 0.078
Co-morbidities
Hypertension 1.32 (0.73–2.39) 0.353
Diabetic mellitus 1.60 (0.67–3.78) 0.288
Pneumoperitoneum duration (min) 0.99 (0.98–1.00) 0.099




HR (95% CI) p Value HR (95% CI) p Value
Surgery duration (min) 0.99 (0.98–1.00) 0.142
Anesthesia duration (min) 0.99 (0.99–1.00) 0.259
Administered dose of remifentanil (µg) 0.98 (0.96–1.01) 0.200
Administered dose of ephedrine (mg) 1.03 (0.98–1.07) 0.162
Intraoperative fluid input and output (mL)
Crystalloid 1.00 (0.99–1.00) 0.444
Colloid 1.00 (0.99–1.00) 0.816
Blood loss 1.00 (1.00–1.01) 0.087
Urine output 1.00 (0.99–1.00) 0.744
Duration of postoperative hospital stay (days) 1.02 (0.88–1.18) 0.769
Initial PSA level, ng/mL 1.03 (1.02–1.04) <0.001 * 1.02 (0.99–1.03) 0.075
Gleason score
6 1 1
7 3.02 (1.18–7.73) 0.021 * 1.62 (0.59–4.46) 0.352
≥8 19.53 (7.74–49.31) <0.001 * 11.07 (3.81–32.19) <0.001 *
Tumor volume (cc)
<1 1 1
≥1 and <5 1.37 (0.65–2.88) 0.408 1.03 (0.45–2.40) 0.940
≥5 10.67 (4.83–23.58) <0.001 * 1.36 (0.32–5.75) 0.674
Surgical margin status
Negative 1 1
Positive 4.38 (2.38–8.06) <0.001 * 1.26 (0.53–3.01) 0.608
Pathological tumor stage
2 1 1
3a 5.72 (2.71–12.07) <0.001 * 4.92 (2.04–11.88) <0.001 *
3b 15.67 (7.26–33.82) <0.001 * 8.86 (2.56–30.72) <0.001 *
Lymph node metastasis
Negative 1 1
Positive 3.67 (1.13–11.95) 0.031 * 1.07 (0.24–4.78) 0.931
* p < 0.05. HR, hazards ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; PSA, prostate specific antigen; RALP,
robot-assisted laparoscopic radical prostatectomy.
Further, the group was not an independent risk factor for radiographic progression
after RALP; however, the following variables were significant predictors (Table 4): duration
of postoperative hospital stay (HR = 1.43, 95% CI: 1.11–1.85; p = 0.007), and pathological
tumor stage 3a and 3b (HR = 9.64, 95% CI: 1.38–67.25; p = 0.022, and HR = 17.61, 95% CI:
1.09–285.07, p = 0.044, respectively).
Table 4. Univariate and multivariate analyses of risk factors for radiographic progression after RALP (n = 114).
Variable
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
Group
control 1 1
dexmedetomidine 0.66 (0.21–2.07) 0.474 0.71 (0.21–2.39) 0.580
Age (years) 1.04 (0.97–1.11) 0.279
Body mass index (kg/m2) 1.09 (0.87–1.36) 0.460
ASA physical status
I 1
II 1.30 (0.39–4.30) 0.673
Co-morbidities
Hypertension 1.87 (0.59–5.91) 0.285
Diabetic mellitus 2.05 (0.45–9.40) 0.355
Pneumoperitoneum duration (min) 0.99 (0.97–1.01) 0.451
Surgery duration (min) 1.00 (0.98–1.02) 0.937
Anesthesia duration (min) 1.00 (0.99–1.02) 0.746




HR (95% CI) p Value HR (95% CI) p Value
Administered dose of remifentanil (µg) 1.01 (0.98–1.05) 0.505
Administered dose of study drug (cc) 1.01 (0.86–1.18) 0.934
Administered dose of ephedrine (mg) 1.03 (0.97–1.10) 0.334
Intraoperative fluid input and output (mL)
Crystalloid 1.00 (0.99 –1.00) 0.716
Colloid 1.00 (0.99–1.00) 0.229
Blood loss 1.00 (1.00–1.01) 0.063
Urine output 1.00 (1.00–1.01) 0.962
Postoperative hospital stays (days) 1.33 (1.08–1.65) 0.008 * 1.43 (1.11–1.85) 0.007 *
Initial PSA level (ng/mL) 1.02 (1.00–1.04) 0.034 * 1.01 (0.97–1.05) 0.632
Gleason score
6 1 1
7 6.95 (0.30–161.01) 0.227 2.74 (0.10–75.96) 0.553
8 or more 37.99 (1.86–776.45) 0.018 * 12.84 (0.54–305.92) 0.115
Tumor volume (cc)
<1 1 1
≥1 and less than 5 7.41 (0.89–61.71) 0.064 2.83 (0.42–19.35) 0.288
5 or more 18.24 (2.12–156.79) 0.008 * 0.23 (0.01–5.77) 0.373
Surgical margin status
Negative 1
Positive 2.18 (0.70–6.77) 0.179
Pathological tumor stage
2 1 1
3a 16.54 (1.93–141.87) 0.011 * 9.64 (1.38–67.25) 0.022 *
3b 27.40 (3.30–227.71) 0.002 * 17.61 (1.09–285.07) 0.044 *
Lymph node metastasis
Negative 1 1
Positive 6.32 (1.37–29.06) 0.018 * 2.20 (0.23–20.85) 0.491
* p < 0.05. HR, hazards ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; PSA, prostate specific antigen; RALP,
robot-assisted laparoscopic radical prostatectomy.
4. Discussion
This is the first randomized trial to demonstrate the effects of intraoperative con-
tinuous infusion of dexmedetomidine on long-term oncologic outcomes in patients with
prostate cancer who have undergone RALP. Low-dose administration of dexmedetomi-
dine at a rate of 0.3–0.4 µg/kg/h from the initiation of anesthesia to the end of pneu-
moperitoneum maintenance did not significantly affect the incidence of post-RALP BCR.
Additionally, there was no beneficial effect on radiographic progression either.
The sympathetic and immunoregulatory effects of dexmedetomidine may underlie its
perioperative benefits in patients with cancer. However, recent in vitro experiments have
reported that dexmedetomidine may have unfavorable effects on patients with cancer, as
observed in breast, lung, colon, and liver cancer cell lines [10,14,18]. The mechanisms un-
derlying the effects of dexmedetomidine on tumor cells are as follows: it directly activates
tumor alpha-2 adrenoreceptors [12,18], affects the capillary diameter or permeability of
tumor cells [10], and drives microstructural changes in the tumor environment, causing
proliferation, local invasion, and metastasis of tumor cells [11]. Additionally, current clin-
ical evidence has raised concerns regarding the perioperative use of dexmedetomidine
in patients with several types of cancer [14–18]. In breast cancer, dexmedetomidine has
promoted cancer progression in vivo and in vitro by acting on alpha-2 adrenoreceptor
and activating extracellular signal-related protein kinases [10–14]. Clinical study in lung
cancer has shown that intraoperative administration of dexmedetomidine is associated
with reduced overall survival rates [16]. Moreover, a study on a mouse model of lung
cancer has demonstrated that dexmedetomidine promoted postoperative metastasis by
augmenting the number of monocytic myeloid-derived suppressor cells (M-MDSCs) via
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alpha-2 adrenoreceptor stimulation [17], and in vitro study suggested that dexmedeto-
midine promotes cancer cell survival in lung cancer through signaling via on alpha-2
adrenoreceptor [18]. Further, a recent clinical study on hepatocellular carcinoma reported
that dexmedetomidine did not significantly affect progression of malignancy; however, in
case of activation of hepatic stellate cells, dexmedetomidine promoted tumor growth and
metastasis [14].
It remains unclear whether dexmedetomidine affects the postoperative prognosis and
outcomes in patients with all types of cancer. Recently, dexmedetomidine was reported
to inhibit esophageal cancer progression via the miR-143-3P/epidermal growth factor
receptor pathway substrate 8 in vivo [7]. Additionally, Owuso et al. performed a retro-
spective study on patients who had undergone cytoreductive surgery with hyperthermic
intraperitoneal chemotherapy and demonstrated that intraoperative and/or early post-
operative continuous infusion of dexmedetomidine was not associated with survival [19].
Apart from the present retrospective analysis and the aforementioned propensity score-
matched retrospective study on patients with non-small cell lung cancer [16], there has
not been any randomized trial to evaluate the influence of dexmedetomidine on long-term
cancer t5outcomes.
Based on the data of the previous randomized controlled trials [19,20], this study
showed that dexmedetomidine did not significantly affect BCR and radiographic pro-
gression in patients with prostate cancer within 4–6 years after RALP. Previous findings
regarding this topic have been inconsistent, and the effect of dexmedetomidine on prostate
cancer cell lines remains unclear. In breast, lung, and colon cancer [10,12,16], dexmedetomi-
dine has been reported to be associated with pro-tumoral effects; however, it has shown to
improve outcomes in patients with ovarian cancer by impeding with the activation of the
chemotherapy drug-resistance pathway [25]. This suggests that dexmedetomidine may not
exhibit similar pro-tumoral effects across all types of cancer. Therefore, the inconsistency
between our findings and those of previous studies may be because this study is the first
to examine the effects of dexmedetomidine on patients with prostate cancer. Further-
more, the average dose of total administered dexmedetomidine in this study was 56.4 µg
(0.3–0.4 µg/kg/h; concentration of 4 µg/mL), which is lower than the dose administered
in previous reports. Animal studies have shown that the metastasis-promoting effects of
dexmedetomidine varied with the dose range. The range of 2.5–10 µg/kg/h has shown
inconsistent results, while a higher dose range of 10–20 µg/kg/h has consistently shown
deleterious effects [10]. The clinical reflection of the dose effects of dexmedetomidine
observed in animal studies remains unclear; however, these findings suggest that the
unfavorable effects of dexmedetomidine in patients may be dose-dependent. The median
intraoperative administered doses of dexmedetomidine in the two previous trials on pa-
tients with lung cancer were 100 µg (57.47–140 µg) [16] and 122 µg (118–146 µg) [17], both of
which are higher doses than that used in this study. Pascal et al., who reported findings that
were consistent with our findings, used a dose of 0.1–0.7 µg/kg/h [19]. These inconsistent
findings further indicate a mixed survival effect of low-dose dexmedetomidine.
This study has several limitations. First, generalization of our results may not be
possible due to the selection bias commonly present in single-center retrospective studies.
However, we may have limited the bias compared with other retrospective observational
studies by controlling for other intraoperative variables in the study with the inclusion
of randomly assigned patients. Second, this study had a limited sample size, given the
original size of the IOP and QTc trials, which warrants the need for future prospective
studies with a larger sample size.
5. Conclusions
In patients with prostate cancer who had undergone RALP, administration of low-dose
dexmedetomidine at a rate of 0.3–0.4 µg/kg/h was not associated with a significant impact
on BCR, which reflects the long-term oncologic outcomes of prostate cancer. Furthermore,
dexmedetomidine did not affect the radiographic progression of prostate cancer following
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RALP. Further animal and prospective studies may be needed to further assess the effects
of dexmedetomidine on prostate cancer.
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